- Home
- JFIN vs XNCR Comparison
JFIN vs XNCR Comparison
Compare JFIN & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFIN
- XNCR
- Stock Information
- Founded
- JFIN 2011
- XNCR 1997
- Country
- JFIN China
- XNCR United States
- Employees
- JFIN N/A
- XNCR N/A
- Industry
- JFIN Finance: Consumer Services
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- JFIN Finance
- XNCR Health Care
- Exchange
- JFIN Nasdaq
- XNCR Nasdaq
- Market Cap
- JFIN 682.1M
- XNCR 547.8M
- IPO Year
- JFIN 2019
- XNCR 2013
- Fundamental
- Price
- JFIN $11.15
- XNCR $12.04
- Analyst Decision
- JFIN
- XNCR Buy
- Analyst Count
- JFIN 0
- XNCR 11
- Target Price
- JFIN N/A
- XNCR $22.20
- AVG Volume (30 Days)
- JFIN 90.9K
- XNCR 1.2M
- Earning Date
- JFIN 11-19-2025
- XNCR 11-05-2025
- Dividend Yield
- JFIN 7.06%
- XNCR N/A
- EPS Growth
- JFIN 33.85
- XNCR N/A
- EPS
- JFIN 4.21
- XNCR N/A
- Revenue
- JFIN $908,895,698.00
- XNCR $146,929,000.00
- Revenue This Year
- JFIN N/A
- XNCR $23.31
- Revenue Next Year
- JFIN N/A
- XNCR N/A
- P/E Ratio
- JFIN $2.68
- XNCR N/A
- Revenue Growth
- JFIN 8.19
- XNCR N/A
- 52 Week Low
- JFIN $5.18
- XNCR $6.92
- 52 Week High
- JFIN $19.23
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- JFIN 44.45
- XNCR 80.54
- Support Level
- JFIN $10.18
- XNCR $10.24
- Resistance Level
- JFIN $11.64
- XNCR $12.63
- Average True Range (ATR)
- JFIN 0.46
- XNCR 0.57
- MACD
- JFIN 0.17
- XNCR 0.11
- Stochastic Oscillator
- JFIN 73.97
- XNCR 76.73
About JFIN Jiayin Group Inc.
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.